Want to see FR:NANO full AI Analyst Report?
NANO Stock Chart & Stats
€35.24
-€0.84(-2.38%)
At close: 4:00 PM EDT
€35.24
-€0.84(-2.38%)
Day’s Range― - ―
52-Week Range€5.66 - €47.66
Previous CloseN/A
Volume28.17K
Average Volume (3M)654.19K
Market Cap
€1.71B
Enterprise Value€986.13
Total Cash (Recent Filing)€52.75M
Total Debt (Recent Filing)€95.32M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Sep 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,619,583
10 Day Avg. Volume711,483
30 Day Avg. Volume654,186
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.00Price Target Upside56.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.21
Revenue Forecast (FY)€34.90M
Bulls Say, Bears Say
Bulls Say
Proprietary Nanoparticle PlatformNBTXR3 is a distinct, platform-level technology engineered to amplify radiotherapy and potentially trigger immune responses. As a platform asset it supports multiple tumor indications and partnership opportunities, offering durable IP-driven differentiation and long-term product extension potential.
Established Pharma CollaborationA material collaboration with Janssen provides development funding, regulatory and commercialization expertise, and milestone/royalty upside. Such alliances materially lower single-company execution risk and can create sustained collaboration revenue streams and validation for long-term commercialization.
High Gross Margin PotentialThe 2025 rebound and reported 100% gross margin suggest the technology can exhibit favorable unit economics once commercialized. Durable high gross margins improve scalability, support partner economics, and make future profitability more attainable if revenue stabilizes across indications or deals.
Bears Say
Persistent Cash BurnOperating and free cash flow have been persistently negative, reflecting ongoing cash burn that erodes runway. Long-term reliance on external financing raises dilution and execution risk and constrains investment in trials and commercialization, undermining sustainable operations absent milestones or revenue.
Weakened Capital StructureNegative shareholders' equity combined with rising debt materially weakens financial flexibility and increases refinancing and covenant risk. This capital-structure stress makes funding expensive and heightens survival risk during trial delays or slower-than-expected partner payments over the medium term.
Revenue Volatility & Unproven RepeatabilityTop-line performance has been inconsistent, with a sharp 2025 rebound following prior-year volatility. That lack of repeatable revenue undermines forecastability of cash flows and the ability to convert high gross margins into sustainable profitability without stable multi-year commercial traction or recurring partner income.
NANO FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €5.66 and its highest was €47.66 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.71B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 57 days.
How were Nanobiotix SA’s earnings last quarter?
Currently, no data Available
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is -0.25.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,619,583 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in FR:NANO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
NANO Stock 12 Month Forecast
Average Price Target
€55.00
▲(56.07% Upside)
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―